Defining the druggability of viral macrodomains in coronaviruses and alphaviruses
Аннотация
Publication date: November 2026 Source: Pharmacological Reviews, Volume 78, Issue 6 Author(s): Banhi Biswas, Rachy Abraham, Jürgen Bosch, Anthony K.L. Leung
Publication date: November 2026 Source: Pharmacological Reviews, Volume 78, Issue 6 Author(s): Banhi Biswas, Rachy Abraham, Jürgen Bosch, Anthony K.L. Leung
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Acta Pharmacologica Sinica, Published online: 13 November 2026; doi:10.1038/s41401-026-01957-9 Structure-based virtual screening with AlphaFold identifies CLIP1-LTK inhibitors
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...